Literature DB >> 8893383

Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis.

S Ishioka1, T Saito, K Hiyama, Y Haruta, A Maeda, S Hozawa, T Inamizu, M Yamakido.   

Abstract

Cytokines released from activated alveolar macrophages and T-lymphocytes affect the accumulation of monocyte-macrophage-lineage cells and therefore play an important role in the formation of sarcoid granuloma. Although it is likely that certain monokines and lymphokines are involved in the development of sarcoid granulomas, the evidence for this is not unequivocal. In an attempt to clear critical cytokines in the development and maintenance of sarcoid granuloma, we have measured the level of seven cytokine mRNA (TNF-alpha, IL-6, IL-8, TGF-beta, PDGF-B, IFN-gamma, and GM-CSF) in cells obtained by BAL from sarcoidosis patients and normal subjects. To detect cytokine mRNA, we employed a reverse transcription-polymerase chain reaction. We report that the levels of TNF-alpha, IL-6, PDGF-B and GM-CSF mRNA were significantly increased in BAL cells from the patients with pulmonary sarcoidosis compared to controls. No significant differences were observed in the mRNA expression of IL-8, TGF-beta and IFN-gamma. A significant correlation of the expression of the mRNA levels of seven cytokines in the same patients with sarcoidosis was observed between IL-8 and TNF-alpha, PDGF-B, and IL-6, IL-8 and IL-6 and TFN-alpha and PDGF-B and IL-8. This finding indicates that at least these four cytokines are involved in the cytokine network at the local alveolar site of chronic granulomatous inflammation. This study adds a report to the literature that supports a role for cytokine, TNF-alpha, IL-6, PDGF and GM-CSF in particular, in the promotion and maintenance of sarcoid granulomatous inflammation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893383

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  4 in total

1.  Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis.

Authors:  M Möllers; S P Aries; D Drömann; B Mascher; J Braun; K Dalhoff
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 2.  Adalimumab for refractory pulmonary sarcoidosis.

Authors:  P A Minnis; M Poland; M P Keane; S C Donnelly
Journal:  Ir J Med Sci       Date:  2015-10-01       Impact factor: 1.568

3.  Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.

Authors:  M I Gabrilovich; J Walrath; J van Lunteren; D Nethery; M Seifu; J A Kern; C V Harding; L Tuscano; H Lee; S D Williams; W Mackay; J F Tomashefski; R F Silver
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

Review 4.  Tocilizumab in the treatment of rheumatoid arthritis and beyond.

Authors:  Anjali Shetty; Rebekah Hanson; Peter Korsten; Munir Shawagfeh; Shiva Arami; Suncica Volkov; Olga Vila; William Swedler; Abdel Naser Shunaigat; Sameer Smadi; Ray Sawaqed; David Perkins; Shiva Shahrara; Nadera J Sweiss
Journal:  Drug Des Devel Ther       Date:  2014-03-28       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.